G Medical Innovations (ASX:GMV) - CEO, Dr Yacov Geva
CEO, Dr Yacov Geva
Source: Globes – Israel
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Mobile health company G Medical Innovations (GMV) has added a new revenue stream to its Independent Diagnostic Testing Facilities (IDTF) platform
  • This platform is a patient monitoring service which allows hospital staff to keep track of a patient’s vital signs remotely
  • G Medical has today announced that it will offer remote patient monitoring services to patients undergoing transcatheter aortic valve replacement (TAVR) treatment
  • Hospitals can now monitor pre and post TAVR patients through G Medical’s AECG Patch technology and mobile cardiac telemetry (MCT) device
  • G Medical is steady on the market and shares are currently trading for 4.2 cents each

Mobile health company G Medical Innovations (GMV) has added a new revenue stream to its Independent Diagnostic Testing Facilities (IDTF) platform.

This platform is a patient monitoring service which allows hospital staff to keep track of a patient’s vital signs remotely.

G Medical has today announced that it will offer remote patient monitoring services to patients undergoing transcatheter aortic valve replacement (TAVR) treatment.

Hospitals can now monitor pre and post TAVR patients through G Medical’s AECG Patch technology and mobile cardiac telemetry (MCT) device.

Additionally, G Medical will receive reimbursements for the service and the price will vary depending on the length of the monitoring period.

“Providing hospital partners with the ability to monitor patients undergoing TAVR treatment through our IDTF platform is another valuable revenue channel,” CEO Dr Yacov Geva said.

“As the addressable market for telehealth grows, we are very confident IDTF will continue to scale up. We are making excellent headway in the U.S. university hospital market and our large sales team is identifying many more opportunities for growth,” he added.

G Medical is steady on the market and shares are trading for 4.2 cents each at 12:25 pm AEST.

GMV by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…